MARKET

ALDX

ALDX

Aldeyra
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.03
+0.01
+0.17%
Closed 16:00 11/15 EST
OPEN
6.06
PREV CLOSE
6.02
HIGH
6.11
LOW
5.96
VOLUME
127.32K
TURNOVER
--
52 WEEK HIGH
12.79
52 WEEK LOW
4.310
MARKET CAP
168.56M
P/E (TTM)
-2.7826
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALDX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALDX News

  • Edited Transcript of ALDX earnings conference call or presentation 7-Nov-19 1:00pm GMT
  • Thomson Reuters StreetEvents.3d ago
  • Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences
  • Business Wire.5d ago
  • Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.6d ago
  • Aldeyra Therapeutics EPS misses by $0.15
  • seekingalpha.11/07 17:37

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About ALDX

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
More

Webull offers Aldeyra Therapeutics Inc (ALDX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.